NYSE$HCA

HCA Holdings Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

HCA Healthcare's financial performance surged in Q3 2021, marked by revenue growth and significant gains from facility sales.

HCA Healthcare reported a strong third quarter in 2021 with revenues of $15.276 billion and net income of $2.269 billion, driven by increased patient volumes and gains on sales of facilities, despite the challenges posed by the Delta variant.

  • Revenues increased to $15.276 billion, compared to $13.311 billion in Q3 2020.
  • Net income attributable to HCA Healthcare, Inc. was $2.269 billion, or $7.00 per diluted share, compared to $668 million, or $1.95 per diluted share, in Q3 2020.
  • Adjusted EBITDA totaled $3.224 billion, compared to $2.053 billion in Q3 2020.
  • Same facility admissions and equivalent admissions increased by 6.8% and 9.3%, respectively.

Headline financials

Total Revenue

$15.3B

Previous: $13.3B+14.8%
EPS (adj)

$4.57

Previous: $1.92+138.0%
Admissions

531.0K

Previous: 506.8K+4.8%
Number of Hospitals

183

Previous: 187-2.1%
Licensed Beds at End of Period

49.0K

Previous: 49.5K-1.1%
Occupancy

70.7%

Previous: 57.0%+24.0%
Average Length of Stay (days)

5.184

Previous: 5.117+1.3%
Capital Expenditures

-$2.39B

Previous: -$2.09B-14.3%
Free Cash Flow

-$116M

Previous: -$1.42B+91.8%
Net Income

$2.27B

Previous: $668M+239.7%
Operating Income

-$1.57B

Previous: -$2.35B+33.3%
Gross Profit

$12.8B

Previous: $11.2B+14.6%
Cash & Equivalents

$1.03B

Previous: $6.59B-84.4%
Total Assets

$49.6B

Previous: $51B-2.9%
Stock-Based Comp

$115M

Previous: $81M+42.0%

Revenue & EPS history

HCA · Revenue · Quarterly

$15.3B

Q3 2021+14.8%vs Q3 2020
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

HCA Healthcare revised its 2021 guidance, projecting revenues between $58.7 to $59.3 billion and adjusted EBITDA between $12.50 to $12.80 billion.

Tailwinds

  • Revenue is expected to be between $58.7 to $59.3 billion.
  • Adjusted EBITDA is projected to be $12.50 to $12.80 billion.
  • Diluted EPS is anticipated to be between $17.20 to $17.80.
  • Capital expenditures are estimated to be approximately $3.7 billion.
  • The guidance reflects current expectations regarding the impact of the COVID-19 pandemic and related government legislation.

Headwinds

  • Guidance excludes the impact of items such as gains or losses on sales of facilities.
  • Guidance excludes the impact of losses on retirement of debt.
  • Guidance excludes the impact of legal claims costs.
  • Guidance excludes the impact of impairment of long-lived assets.
  • The Company's guidance is subject to a number of known and unknown uncertainties and risks.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.9%

Avg return

30 days after

47%

31 / 66 earnings

Positive

+16.1%

Q2 2020

Best reaction

-21.9%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.2%-8.3%-16.8%
Q4 2025+6.2%+3.4%+11.3%
Q3 2025+1.5%+6.4%+11.6%
Q2 2025+0.8%+3.1%+3.8%
Q1 2025-4.0%+1.1%+10.3%
Q4 2024-3.8%+0.7%-2.7%
Q3 2024-10.6%-9.5%-18.5%
Q2 2024+5.7%+9.0%+17.7%
Q1 2024-0.9%-1.5%+1.5%
Q4 2023+6.3%+7.9%+8.7%
Q3 2023-6.5%-6.5%+5.0%
Q2 2023-3.2%-2.9%-3.2%
Q1 2023+5.7%+2.7%+4.3%
Q4 2022-0.6%+2.6%-2.2%
Q3 2022+0.8%+4.3%+10.3%
Q2 2022+9.6%+12.9%+18.6%
Q1 2022-21.9%-21.2%-24.0%
Q4 2021-1.4%-1.1%+5.5%
Q3 2021-7.0%-5.6%-8.1%
Q2 2021+14.5%+14.2%+13.3%
Q1 2021+2.5%+0.7%+4.5%
Q4 2020+3.7%+5.9%+5.6%
Q3 2020-4.4%-9.3%+12.5%
Q2 2020+16.1%+14.6%+21.2%
Q1 2020-5.4%-2.4%-2.2%
Q4 2019+2.6%-2.0%-10.1%
Q3 2019+6.2%+5.3%+10.3%
Q2 2019-8.7%-13.0%-17.4%
Q1 2019-1.1%+0.2%-2.3%
Q4 2018+5.6%+6.1%+5.5%
Q3 2018+3.5%+4.2%+12.0%
Q2 2018+14.9%+14.7%+21.4%
Q1 2018+2.1%+1.9%+7.7%
Q4 2017+3.6%+2.1%+1.9%
Q3 2017+0.9%+0.3%+11.6%
Q2 2017-5.2%-6.6%-7.9%
Q1 2017-1.2%-0.4%-0.1%
Q4 2016+3.4%+5.7%+10.2%
Q3 2016-2.1%-4.5%-9.6%
Q2 2016-1.1%-3.8%-4.8%
Q1 2016-1.7%
Q4 2015+3.1%
Q3 2015-0.1%
Q2 2015-2.8%
Q1 2015-1.2%
Q4 2014-1.7%
Q3 2014-2.1%
Q2 2014+4.1%
Q1 2014-1.2%
Q4 2013-1.0%
Q3 2013-5.1%
Q2 2013+0.1%
Q1 2013+3.8%
Q4 2012-1.1%
Q3 2012+8.0%
Q2 2012+1.1%
Q1 2012-1.1%
Q4 2009+3.5%
Q4 2011+3.5%
Q3 2011+2.6%
Q3 2010+2.6%
Q2 2011-20.6%
Q2 2010-20.6%
Q1 2011-0.2%
Q1 2010-0.2%
Q4 2010-0.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro